Technical Snapshots for these Drug Delivery Stocks -- Delcath Systems, Valeant Pharma, PetMed Express, and Adamis Pharma

NEW YORK, September 1, 2017 /PRNewswire/ --

If you want a Stock Review on DCTH, VRX, PETS, or ADMP then come over to and sign up for your free customized report today. The market for Drug Delivery technology has expanded rapidly in recent years, with impressive sales growth and important trends, according to a Visiongain report. These technologies provide pharmaceutical companies with novel strategies for the delivery of biologically active drug candidates. This morning, shifts focus on Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) , PetMed Express Inc. (NASDAQ: PETS), and Adamis Pharmaceuticals Corp. (NASDAQ: ADMP). Access's complimentary reports for today's stocks line-up at: Delcath Systems 

Shares in New York headquartered Delcath Systems Inc. saw a slight drop of 0.45%, ending Thursday's trading session at $0.11. The stock recorded a trading volume of 34.22 million shares. The Company's shares have surged 54.69% in the last one month and 453.00% over the last three months. The stock is trading 22.95% below its 50-day moving average. Moreover, shares of Delcath Systems, which focuses on the treatment of primary and metastatic liver cancers, have a Relative Strength Index (RSI) of 44.15.

On August 28th, 2017, Delcath Systems announced that it has negotiated an agreement for the extinguishment of its 2016 Convertible Notes from the holder of the majority of the Notes. The transaction is contingent upon the Company effecting a reverse stock split, which requires shareholder approval through the current consent solicitation. If fully executed, the agreement will extinguish approximately 90% of the remaining $12.6 million in debt related to the Convertible Notes. Visit us today and access your complete report on DCTH for free at: Valeant Pharmaceuticals International 

Laval, Canada headquartered Valeant Pharmaceuticals International Inc.'s stock rose 1.74%, closing the day at $13.42 with a total trading volume of 10.33 million shares. The Company's shares have advanced 7.27% in the previous three months. The stock is trading 3.72% below its 200-day moving average. Additionally, shares of Valeant Pharma, which operates as a pharmaceutical and medical device company worldwide, have an RSI of 33.92.

On August 03rd, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with an increase of the target price from $19 a share to $21 a share.

On August 16th, 2017, Valeant Pharma announced that the US FDA confirmed that it intends to issue a Voluntary Action Indicated inspection classification for the Company's Bausch + Lomb manufacturing facility in Tampa, Florida, as part of a forthcoming Establishment Inspection Record for the facility. With this confirmation, manufacturing uncertainties related to current and upcoming regulatory submissions will be eliminated for products manufactured at the Tampa facility. The complimentary research report on VRX can be accessed at: PetMed Express 

On Thursday, shares in Delray Beach, Florida headquartered PetMed Express Inc. recorded a trading volume of 1.03 million shares. The stock ended the day 2.13% lower at $36.27. The Company's shares have advanced 1.34% in the previous three months and 57.22% on an YTD basis. The stock is trading above its 200-day moving average by 24.66%. Furthermore, shares of PetMed Express, which operates as a pet pharmacy in the US, have an RSI of 31.03.

On August 23rd, 2017, PetMed Express issued the following statement in response to market activity in its common stock: "A false and defamatory "report" was published today by Aurelius Value. We believe that this "report" was intended to severely manipulate our stock price downward in support of short sellers. PetMed Express, Inc. categorically denies the allegations and its implications. We are in the process of reporting this manipulation to the appropriate regulators."

On August 24th, 2017, research firm Sidoti upgraded the Company's stock rating from 'Neutral' to 'Buy'. Register for free on and download the research report on PETS at: Adamis Pharmaceuticals 

San Diego, California headquartered Adamis Pharmaceuticals Corp.'s stock climbed 0.93%, finishing yesterday's session at $5.45 with a total trading volume of 648,757 shares. The Company's shares have advanced 25.29% in the last one month, 19.78% in the previous three months, and 73.02% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.48% and 36.83%, respectively. Additionally, shares of Adamis Pharma, which develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the US, have an RSI of 62.73. Get free access to your research report on ADMP at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

DST has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Phone number: (207)331-3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa 

  CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.